News | August 09, 2022
Briefs: Zydus Lifesciences and Kimia Biosciences
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Subscribe To Our Newsletter & Stay Updated
